NCT04693039View on ClinicalTrials.gov

Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions
Parkinson Disease
Interventions
DRUG

Phenlarmide

Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.

DRUG

Placebo

Dosage form：Tablet; Give the medicine once a day，4 weeks is a cycle of administration, a total of 3 cycles of administration.

Trial Locations (1)

100053

Chen Biao, Beijing

All Listed Sponsors
collaborator

Xuanwu Hospital, Beijing

OTHER

lead

Shijiazhuang Yiling Pharmaceutical Co. Ltd

INDUSTRY

NCT04693039 - Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets | Biotech Hunter | Biotech Hunter